-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Maintains Strong Buy on ADMA Biologics, Raises Price Target to $32

Benzinga·05/08/2025 17:26:36
Listen to the news
Raymond James analyst Elliot Wilbur maintains ADMA Biologics (NASDAQ:ADMA) with a Strong Buy and raises the price target from $25 to $32.